Related Experiment Video
Updated: May 16, 2026

Comparative Study on the Polysaccharide Contents and Antioxidant Activities of Hippophae rhamnoides subsp. sinensis and Hippophae gyantsensis
Published on: August 15, 2025
Prebiotic activity and antidiabetic potential of Ginkgo isomalto-oligosaccharides
Yu Chen1,2, Xinyi Zhang2, Tingting Li1,2,3
1State Key Laboratory for the Development and Utilization of Forest Food Resources, Nanjing Forestry University, Nanjing, Jiangsu 210037, China. litingting@njfu.edu.cn.
Abstract:
This study systematically investigates the prebiotic and antidiabetic potential of a novel oligosaccharide derived from Ginkgo, designated Ginkgo isomalto-oligosaccharide (G-IMO), in comparison with that of conventional corn-derived isomalto-oligosaccharides (C-IMOs). Its stability was assessed under simulated gastrointestinal digestion and under different pH (3.0-11.0) and temperature (4-70 °C) conditions. The effects of G-IMO on probiotic growth, glucose metabolism, and cell viability were further evaluated by measuring bacterial OD600, medium pH, short-chain fatty acid production, Caco-2 cell viability, glucose uptake and transport, glucose transporter expression, and apoptosis. The results demonstrated that G-IMO significantly promoted the growth and proliferation of Lactobacillus plantarum and Bifidobacterium adolescentis compared to C-IMOs. In Caco-2 cells, G-IMO effectively attenuated glucose consumption and transport. Moreover, G-IMO exhibited high resistance to degradation during simulated digestion. It maintained functional activity across a broad pH range and temperature conditions. In conclusion, G-IMO demonstrates stronger prebiotic efficacy and antidiabetic potential than C-IMOs. These findings position G-IMO as a promising functional ingredient for developing dietary interventions aimed at supporting gut health and regulating blood glucose levels.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Glinides
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Sulfonylureas